Real-World study tracks Ozanimod's Long-Term impact on MS patients

NCT ID NCT05335031

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study followed 450 people with relapsing-remitting multiple sclerosis (RRMS) in Germany who were already prescribed ozanimod (Zeposia). Over three years, researchers collected data on how long patients stayed on the drug, its effect on quality of life, and any side effects. The goal was to see how well the medication works outside of a controlled clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ozanimod (Zeposia)
What this could lead to: If successful, this study could confirm that ozanimod is a practical, long-term option for managing relapsing-remitting MS in real-world settings.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment, only gathers data on existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

Universitätsklinikum Dresden, MS Ambulanz

Dresden, Saxony, 01307, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.